Clinical trials: in Iceland
Fluid Accumulation, Fluid Therapy
Fluid Administration and Fluid Accumulation in the Intensive Care Unit
The goal of this international inception cohort study is to describe fluid administration during admittance to the intensive care unit (ICU), and provide contemporary epidemiological data on fluid accumulation, risk factors…
- Conditions
- Fluid Accumulation, Fluid Therapy, Fluid Overload
- Trial name
- FLUID-ICU (NCT06258616)
- Where
- 21 sites in Denmark, Finland and 9 more
- Volunteers
- 1,755 people
- Sponsor
- Nordsjaellands Hospital
Hyperoxaluria, Cystinuria
Prospective Research Rare Kidney Stones (ProRKS)
The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase…
- Conditions
- Hyperoxaluria, Cystinuria, Dent Disease, Lowe Syndrome
- Trial name
- ProRKS (NCT02780297)
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type…
- Trial name
- AURORA (NCT02102165)
- Testing
- metastatic lesion biopsy
- Where
- 52 sites in Belgium, Germany and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Jules Bordet Institute
Alzheimer´s Disease
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
- Trial name
- AD Biomarker (NCT07741526)
- Testing
- NPI-001
- Where
- 4 sites in Denmark, Iceland
- Volunteers
- 33 people
- Sponsor
- Arctic Therapeutics
Obstructive Sleep Apnea
MicroRNAs as Biomarkers for Obstructive Sleep Apnea
Although obstructive sleep apnea (OSA) is a common disorder, there are no blood biomarkers for identification and management of these patients.
- Trial name
- MIR-OSA (NCT06189755)
- Testing
- Positive Airway Pressure
- Where
- 3 sites in United States, Iceland
- Volunteers
- 500 people
- Sponsor
- University of Pennsylvania
Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA).
- Conditions
- Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
- Trial name
- HCCAA (NCT07716865)
- Testing
- NACA
- Where
- Iceland
- Volunteers
- 15 people
- Sponsor
- Arctic Therapeutics
Breast Cancer
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
- Trial name
- OlympiA (NCT02032823)
- Testing
- Olaparib
- Where
- 698 sites in United States, Argentina and 22 more
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
Primary Hyperoxaluria, Dent Disease
Rare Kidney Stone Consortium Patient Registry
The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria (PH), Dent disease, Cystinuria and APRT deficiency.
- Conditions
- Primary Hyperoxaluria, Dent Disease, Cystinuria, APRT Deficiency
- Trial name
- RKSC (NCT00588562)
- Where
- 4 sites in United States, Iceland
- Volunteers
- 730 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder
Behavioral Activation for Depression and Habitual Rumination
Depressive rumination, a negative thinking style characterized by repetitive and passive thoughts about the causes, meanings, and consequences of one's feelings and distress, is often described as being a habitual response…
- Trial name
- MoodHab (NCT06322420)
- Testing
- Behavioural Activation (BA)
- Where
- Iceland
- Volunteers
- 120 people
- Sponsor
- University of Iceland
University Students, Sleep Problems
Light Therapy for University Students
The effects of light therapy on well-being among university students was investigated. A three-week intervention study examined whether the use of light glasses improved sleep quality and concentration and reduced symptoms of…
- Conditions
- University Students, Sleep Problems, Well-being, Concentration Performance
- Trial name
- NCT07659171
- Testing
- Light Glasses (Experimental), Light Glasses (Comparison)
- Where
- Iceland
- Volunteers
- 39 people
- Sponsor
- Reykjavik University
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.
- Trial name
- CANOPY-1 (NCT03631199)
- Testing
- canakinumab, pembrolizumab, carboplatin
- Where
- 152 sites in United States, Argentina and 39 more
- Volunteers
- 673 people
- Sponsor
- Novartis Pharmaceuticals
Fluid Overload
Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.
This study evaluates the benefits and harms of goal directed fluid removal with furosemide versus placebo in critical ill adult patients with fluid overload in the intensive care unit.
- Trial name
- GODIF (NCT04180397)
- Testing
- Furosemide, Isotonic saline
- Where
- 29 sites in Australia, Czechia and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Morten H. Bestle
Breast Cancer, Circadian Rhythms
The Effects of Light Therapy to Treat Cancer-related Side Effects
Severe fatigue, depression, sleep problems and cognitive impairment are the most commonly reported side effects of cancer treatment.
- Conditions
- Breast Cancer, Circadian Rhythms, Fatigue, Sleep Disturbance
- Trial name
- NCT04418856
- Testing
- Light Glasses (Experimental), Light Glasses (Comparison)
- Where
- Iceland
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Reykjavik University
Intracerebral Hemorrhage, Intracerebral Haemorrhage
International Care Bundle Evaluation in Cerebral Hemorrhage Research
Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality.
- Conditions
- Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke
- Trial name
- I-CATCHER (NCT06429332)
- Testing
- Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 3,500 people
- Sponsor
- Region Skane
Obstructive Sleep Apnea
Metabolomics of Obstructive Sleep Apnea
This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and…
- Trial name
- MOSA (NCT04572269)
- Testing
- No Intervention
- Where
- 2 sites in United States, Iceland
- Volunteers
- 388 people
- Sponsor
- University of Pennsylvania
Inflammatory Bowel Diseases (IBD), Crohn Disease (CD)
NORDTREAT Prospective Study on Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), primarily ulcerative colitis (UC) and Crohn's disease (CD), is a chronic disease entity affecting individuals of all ages, and which may severely impact the lives of the patients and their…
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT05414578
- Where
- 17 sites in Denmark, Iceland and 2 more
- Volunteers
- 366 people
- Sponsor
- University of Southern Denmark
Intrusive Memories of Traumatic Event(s)
The Lóa Study: A Brief Digital Intervention for Women With Intrusive Memories in the SAGA Cohort
Intrusive memories are sensory memories of a traumatic event(s) that spring to mind involuntarily, and can evoke strong emotions and disrupt functioning in daily life.
- Trial name
- NCT05849337
- Testing
- Brief imagery-competing task, Brief psychoeducation and signposting task, Treatment as usual (TAU)
- Where
- Iceland
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- University of Iceland
Frailty Syndrome, Prehabilitation
Multimodal Prehabilitation of Frail Patients Undergoing Elective Knee or Hip Replacement
Background: Frailty is a geriatric syndrome of reduced physiologic reserve that increases surgical risk and is common among older adults undergoing hip or knee replacement.
- Conditions
- Frailty Syndrome, Prehabilitation, Arthroplasties, Knee Replacement, Arthroplasties, Hip Replacement
- Trial name
- NCT07465159
- Testing
- Multimodal Prehabilitation
- Where
- Iceland
- Volunteers
- 50 people
- Sponsor
- University of Iceland
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
- Trial name
- NCT04270760
- Testing
- Olpasiran
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 281 people
- Sponsor
- Amgen